Project Grant K08AI199219
- Federal Grant Award Summary Yale University received a $125,809 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2027. This award supports research investigating how non-antibiotic prescription medications disrupt the intestinal microbiome and increase susceptibility to gastrointestinal infections. The research builds upon preliminary...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Yale University a Project Grant of $194,904 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 9, 2026, with an ultimate completion date of March 31, 2031. This award supports a five-year research training and investigation program led by Dr. Eric I. Elliott, MD, PhD, to advance understanding of carnitine metabolism reprogramming in sepsis. The research employs...
- Federal Grant Award Summary Yale University received a $4.9 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 14, 2025, with a completion date of June 30, 2029. The grant supports biomedical research investigating the mechanistic pathways by which gut microbiota and white adipose tissue control the CD4 T-cell compartment and facilitate T-cell migration from the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $3.52 million to Sloan-Kettering Institute for Cancer Research under the Allergy and Infectious Diseases Research program (CFDA 93.855) on March 1, 2026, for a four-year project period concluding February 28, 2030. The project develops computational and clinical tools to prevent gut-borne bloodstream infections in immunocompromised patients through microbiome-based interventions. Deliverables...
- Federal Grant Award Summary New York University School of Medicine received a $847,217 Project Grant award dated June 5, 2026, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The five-year award, extending through May 31, 2031, funds research into dietary and microbial strategies to suppress antibiotic-induced antimicrobial resistance (AMR) in the gut microbiome. The research will analyze a...
- Federal Grant Award Summary Yale University received a $453,629 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 8, 2025, with completion targeted for June 30, 2027. The grant supports development and application of PHAGE-SEQ, a high-throughput technology combining phage display of nanobodies (VHH recognition domains derived from camelid heavy chain-only immunoglobulins)...
- Federal Grant Award Summary Yale University received a $735,631 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with completion targeted for March 31, 2031. The research focuses on investigating the origin and functional properties of CX3CR1+ neutrophils, a novel neutrophil population with distinct biological characteristics compared to canonical neutrophils....
- Federal Grant Award Summary Yale University received a $710,638 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 1, 2026, with completion targeted for April 30, 2031. The award supports fundamental research into the molecular mechanisms of sheathed flagellar structures in Helicobacter pylori, a pathogenic bacterium responsible for peptic ulcers, chronic gastritis, and gastric...
- Federal Project Grant Award Summary Yale University received a $2,685,326 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded July 7, 2025, with a completion date of June 30, 2029. The award supports biomedical research investigating the regulation of neutrophil plasticity, heterogeneity, and functional ambivalency by Wnt5 proteins in the context of colitis. The research focuses on...
- Federal Grant Award Summary Funding Agency: National Institute of Allergy and Infectious Diseases (NIAID) Program: Allergy and Infectious Diseases Research (CFDA 93.855) Award Amount: $463,375 Award Date: February 2, 2026 Project Period: February 2, 2026 – January 31, 2028 Harvard College's Office for Sponsored Programs is conducting high-throughput screening research to discover novel antimicrobial metabolites produced by human gut bacteria that contribute to colonization resistance—the...
Grant Award Summary Yale University received a $192,330 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 11, 2026, with completion targeted for May 31, 2031. The award funds research to elucidate the causal role of intestinal microbiota in sepsis mortality, a life-threatening condition responsible for approximately 270,000 annual deaths and $38 billion in U.S. healthcare costs. The research will utilize established murine sepsis models combined with microbiota taxonomic sequencing, metagenomics, advanced bioinformatic techniques, and germ-free mouse systems to characterize microbial features and specific bacterial members that correlate with, predict, and cause sepsis outcomes. The grant supports two primary research objectives: identifying baseline stool microbial features associated with and predictive of sepsis outcomes, and determining how colonization with immunostimulatory microbes heightens sepsis mortality. The project will holistically characterize host immunologic responses and provide scientific evidence addressing why patients with similar medical backgrounds experience vastly different sepsis outcomes despite receiving comparable medical treatment. This research is expected to advance understanding of gut dysbiosis mechanisms underlying gram-negative bacteremia and develop potential therapeutic targets to improve survival rates in sepsis patients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $192.3k | 6/12/26 |